Published in final edited form as:

J Med Chem. 2017 July 13; 60(13): 5699–5716. doi:10.1021/acs.jmedchem.7b00426.

Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants

Ashley N. Matthew[†], Jacqueto Zephyr[†], Caitlin. J. Hill^{†,‡}, Muhammad Jahangir^{†,§}, Alicia Newton[‡], Christos J. Petropoulos[‡], Wei Huang[‡], Nese Kurt-Yilmaz[‡], Celia A. Schiffer^{†,*}, and Akbar Ali^{†,*}

[†]Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States

[‡]Monogram Biosciences, South San Francisco, California 94080, United States

Abstract

A substrate envelope-guided design strategy is reported for improving the resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position that predominantly interact with the invariant catalytic triad of the protease. Exploration of structure-activity relationships showed that inhibitors with small hydrophobic substituents at the 3-position of P2 quinoxaline maintain better potency against drug resistant variants, likely due to reduced interactions with residues in the S2 subsite. In contrast, inhibitors with larger groups at this position were highly susceptible to mutations at Arg155, Ala156 and Asp168. Excitingly, several inhibitors exhibited exceptional potency profiles with EC₅₀ values < 5 nM against major drug resistant HCV variants. These findings support that inhibitors designed to interact with evolutionarily constrained regions of the protease, while avoiding interactions with residues not essential for substrate recognition, are less likely to be susceptible to drug resistance.

Graphical abstract

Corresponding Authors: Akbar Ali: Phone: +1 508 856 8873; Fax: +1 508 856 6464; Akbar.Ali@umassmed.edu. Celia A. Schiffer: Phone: +1 508 856 8008; Fax: +1 508 856 6464; Celia.Schiffer@umassmed.edu.

[#]Department of Chemistry, Tufts University, Medford, Massachusetts 02155, United States

[§]Department of Chemistry, GC University Lahore, Katchery Road, Lahore 54000, Pakistan

ORCID

Akbar Ali: 0000-0003-3491-791X

Celia A. Schiffer: 0000-0003-2270-6613

Notes

The authors declare no competing financial interest. AN, CJP and WH are employees of Monogram Biosciences.

Accessions Codes

The PDB accession codes for inhibitors **18f**- and **19b**-bound WT NS3/4A protease X-ray structures are 5VP9 and 5VOJ. Authors will release the atomic coordinates and experimental data upon article publication.

Supporting Information:

The Supporting Information is available free of charge on the ACS Publications website at DOI:

Tables S1–S3

Synthesis of intermediates and final compounds

Protein expression, purification and K_m experiments

Molecular formula strings

INTRODUCTION

Hepatitis C virus (HCV) infects over 130 million people globally and is the leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.¹ HCV is known as a “silent killer” as a majority of affected patients remain unaware of their infection, and over time the acute infection progresses to chronic liver disease.² The rate of cirrhosis is estimated to increase from 16% to 32% by the year 2020 due to the high number of untreated patients.³ Thus, there is an urgent need to ensure that patients infected with HCV receive proper treatment. However, HCV infection is difficult to treat, as the virus is genetically diverse with six known genotypes (genotype 1–6), each of which is further sub-divided into numerous subtypes.⁴ Genotype 1 (GT1) and genotype 3 (GT3) are the most prevalent accounting for 46% and 30% of global infections, respectively.^{4,5} Therapeutic regimen and viral response are largely genotype dependent with most treatments being efficacious only against GT1.⁶

The recent advent of direct-acting antivirals (DAAs) targeting essential viral proteins NS3/4A, NS5A, and NS5B has remarkably improved therapeutic options and treatment outcomes for HCV infected patients.^{6,7} Four new all-oral combination treatments have been approved by the US FDA: (1) sofosbuvir/ledipasvir,⁸ (2) ombitasvir/paritaprevir/ritonavir/dasabuvir,⁹ (3) elbasvir/grazoprevir,¹⁰ and (4) sofosbuvir/velpatasvir.¹¹ The DAA-based therapies are highly effective against GT1 with sustained virological response (SVR) rates greater than 90%.^{6,7} However, most of the FDA approved treatments and those in clinical development are not efficacious against other genotypes, especially GT3.⁷ Moreover, except for sofosbuvir, all current DAAs are susceptible to drug resistance.¹² Therefore, more robust DAAs need to be developed with higher barriers to drug resistance and a broad spectrum of activity against different HCV genotypes.

The HCV NS3/4A protease is a major therapeutic target for the development of pan-genotypic HCV inhibitors.^{13,14} The NS3/4A protease inhibitors (PIs) telaprevir¹⁵ and boceprevir¹⁶ were the first DAAs approved for the treatment of HCV GT1 infection in combination therapy with pegylated-interferon and ribavirin.^{17,18} Three recently approved PIs, simeprevir,¹⁹ paritaprevir²⁰ and grazoprevir,²¹ (Figure 1) are integral components of various combination therapies currently used as the standard of care for HCV infected patients.^{6,7,14} Two other NS3/4A PIs, asunaprevir²² and vaniprevir,²³ have been approved in Japan. In addition, a number of next generation NS3/4A PIs are in clinical development including glecaprevir²⁴ and voxilaprevir²⁵ (Figure 1).

All NS3/4A PIs share a common peptidomimetic scaffold and are either linear or macrocyclic; the macrocycle is located either between P1–P3 or P2–P4 moieties.¹⁴ In addition, these inhibitors contain a large heterocyclic moiety attached to the P2 proline, which significantly improves inhibitor potency against wild-type (WT) NS3/4A protease.^{26,27} However, all NS3/4A PIs are susceptible to drug resistance, especially due to single site mutations at protease residues Arg155, Ala156 and Asp168.^{28,29} Notably, D168A/V mutations are present in nearly all patients who fail treatment with PIs.¹² Moreover, natural polymorphisms at this position are responsible for significantly reduced inhibitor potency against GT3.³⁰ We previously determined the molecular mechanisms of drug resistance due to single site mutations by solving high-resolution crystal structures of PIs bound to WT and mutant proteases.^{31–34} These crystal structures revealed that the large heterocyclic P2 moieties of PIs bind outside the substrate binding region, defined as the substrate envelope, and make extensive interactions with residues Arg155, Ala156 and Asp168.^{32,33} The inhibitor P2 moiety induces an extended S2 subsite by forcing the Arg155 side chain to rotate nearly 180° relative to its conformation in substrate complexes.³¹ This altered Arg155 conformation is stabilized by electrostatic interactions with Asp168, providing additional hydrophobic surface that is critical for efficient inhibitor binding. Disruption of electrostatic interactions between Arg155 and Asp168 due to mutations underlies drug resistance against NS3/4A PIs.^{31–33,35} Moreover, we have shown that structural differences at the P2 moiety largely determine the resistance profile of these inhibitors.³⁶

Grazoprevir (MK-5172, **1**), one of the most potent HCV NS3/4A PIs, has a unique binding mode where the P2 quinoxaline moiety interacts with residues of the catalytic triad, avoiding direct interactions with Arg155 and Asp168 (Figure 2).³² As a result, **1** has an excellent potency profile across different genotypes and relatively low susceptibility to drug resistance due to mutations at Arg155 and Asp168.^{21,37} However, **1** is highly susceptible to mutations at Ala156, mainly due to steric clashes of larger side chains with the P2–P4 macrocycle. We have shown that the P1–P3 macrocyclic analogue 5172-mcP1P3 (**2**) avoids this steric clash while still maintaining the unique binding mode of **1** (Figure 2).³⁸ Compound **2**, though slightly less potent than **1** against WT HCV, has an excellent potency profile with EC₅₀ values in the single digit nanomolar range against drug resistant variants including A156T. Similar to **1**, the P2 quinoxaline moiety in **2** stacks against the catalytic residues His57 and Asp81 and largely avoids direct interactions with residues around the S2 subsite.³⁸ But unlike **1**, the flexible P2 quinoxaline moiety in **2** better accommodates mutations at Ala156, resulting in an overall improved resistance profile.^{36,38} Thus, the P1–P3 macrocyclic analogue **2** is a promising lead compound for structure-activity relationship (SAR) studies to further improve potency against drug resistant variants and other genotypes.

The substrate envelope model provides a rational approach to design NS3/4A PIs with improved resistance profiles by exploiting interactions with the protease residues essential for function and avoiding direct contacts with residues that can mutate to confer drug resistance.^{39–41} Another approach applied to design PIs with improved resistant profiles involves incorporation of conformational flexibility that can allow the inhibitor to adapt to structural changes in the protease active site due to mutations.³⁵ Here, we describe a

structure-guided strategy that combines these two approaches and, together with our understanding of the mechanisms of drug resistance, led to the design of NS3/4A PIs with exceptional potency profiles against major drug resistant HCV variants. Based on the lead compound **2**, a series of analogues were designed and synthesized with diverse substituents at the 3-position of P2 quinoxaline moiety. Investigation of SARs identified P2 quinoxaline derivatives that predominantly interact with the invariant catalytic triad and avoid contacts with the S2 subsite residues. The results indicate that combining the substrate envelope model with optimal conformational flexibility provides a general strategy for the rational design of NS3/4A PIs with improved resistance profiles.

CHEMISTRY

The NS3/4A PIs with diverse P2 quinoxaline moieties were synthesized using the reaction sequence outlined in Scheme 1. A Cs_2CO_3 -mediated $\text{S}_{\text{N}}2$ reaction of 3-substituted quinoxalin-2-ones **8a-g** with the activated proline derivative **3** provided the key P2 intermediates **9a-g** in 75–90% yield. The alternate $\text{S}_{\text{N}}\text{Ar}$ reaction between activated quinoxaline derivatives and Boc-protected hydroxy-proline resulted in lower yields, and purification of the resulting P2 acid products was significantly more challenging. The 3-substituted 7-methoxy-quinoxalin-2-ones **8ab** and **8d-e** were prepared by condensation reactions of 4-methoxybenzene-1,2-diamine with the corresponding ethyl glyoxylates (see Supporting Information for details). The 3-chloro-7-methoxyquinoxalin-2-one **8c** was prepared according to a reported method.²¹

The P1–P3 macrocyclic PIs were assembled from the P2 intermediates **9a-g** using a sequence of deprotection and peptide coupling steps followed by the ring-closing metathesis (RCM) reaction (Method A). Removal of the Boc group in **9a-g** using 4 N HCl provided the amine salts **10a-g**, which were coupled with the amino acid **11** in the presence of HATU and DIEA to yield the P2–P3 ester intermediates **12a-g**. Hydrolysis of these esters with LiOH and reaction of the resulting carboxylic acids **13a-g** with the P1–P1' fragments **14**⁴² and **15**⁴³ under HATU/DIEA coupling conditions provided the bis-olefin intermediates **16a-g** and **17a-e**. Finally, cyclization of the bis-olefin intermediates was accomplished using a highly efficient RCM catalyst Zhan 1B, and provided the inhibitors **18b-g** and **19a-e** in 45–80% yield. Interestingly, RCM reactions of bis-olefins **17a-e** bearing the 1-methylcyclopropylsulfonamide provided higher yield than the corresponding cyclopropylsulfonamide analogues **16a-g**. Finally, removal of the Boc group and reaction of the resulting amine salts **20a-g** and **21a-e** with the *N*-(cyclopentylloxycarbonyloxy)-succinimide in the presence of DIEA afforded the inhibitors **22a-g** and **23a-e** with the *N*-terminal cyclopentyl P4 moiety.

A subset of inhibitors was synthesized using an alternate reaction sequence that allowed late-stage modification at both the P1' and P4 positions as illustrated in Scheme 2 (Method B). The P2–P3 acid intermediates **13a-d** were reacted with the commercially available amine salt **24** under HATU/DIEA coupling conditions to afford the bis-olefin intermediates **25a-d**. RCM reaction in the presence of Zhan 1B catalyst provided the macrocyclic intermediates **26a-d** in 75–90% yield, which was better than that obtained in the presence of the P1' acylsulfonamide. The P1–P3 macrocyclic core intermediates **26a-d** can be modified in either

direction after removing the C- or N-terminal protecting groups. Thus, hydrolysis of the C-terminal ethyl ester with LiOH provided the acids **27a-d**, which were then reacted with either cyclopropylsulfonamide **28** or 1-methylcyclopropylsulfonamide **29** in the presence of CDI and DBU to afford the final inhibitors **18b-d** and **19a-d**. The N-terminal *tert*-butyl capping group was replaced with the cyclopentyl moiety as described earlier to provide the target inhibitors **22a-d** and **23a-d**.

RESULTS AND DISCUSSION

Our goal was to develop a structure-guided design strategy to improve the resistance profile of HCV NS3/4A PIs based on the substrate envelope model.^{39,40} Compound **2** is an attractive scaffold for exploring this strategy due to the unique structural features: (1) the P2 quinoxaline moiety that predominantly interacts with the highly conserved catalytic residues Asp81 and His57 and (2) the conformational flexibility that allows the inhibitor to efficiently accommodate structural changes in the S2 subsite due to resistance mutations. Despite these promising features, optimization of substituents at the P2 quinoxaline and the N-terminal capping may be key to discovering analogues with improved potency and resistance profiles. Therefore, efforts were focused on exploration of SARs at the P2 quinoxaline moiety in **2**, specifically substituting the ethyl group at the 3-position that directly interacts with protease S2 subsite residues Arg155 and Ala156. The SAR strategy was based on insights from detailed structural analysis of **1** and **2** bound to wild-type NS3/4A protease and drug resistant variants.^{32,38} Based on these insights, we hypothesized that small hydrophobic groups at the 3-position of the quinoxaline would be preferred for retaining inhibitor potency against drug resistant variants, but larger groups that make extensive interactions with Arg155, Ala156 and Asp168 would result in inhibitors highly susceptible to mutations at these positions. To test this hypothesis, a series of inhibitors with diverse substituents at the 3-position of P2 quinoxaline were designed and synthesized.

The potency and resistance profiles of NS3/4A PIs were assessed using biochemical and replicon assays. The enzyme inhibition constants (*K_i*) were determined against wild-type GT1a NS3/4A protease, drug-resistant variant D168A, and GT3a NS3/4A protease (Table 1). The cellular antiviral potencies (EC₅₀) were determined using replicon-based antiviral assays against wild-type HCV and drug-resistant variants R155K, A156T, D168A, and D168V (Table 2). Grazoprevir (GZR, **1**) was used as a control in all assays. The observed antiviral potencies are generally higher than protease inhibitory potencies, likely because biochemical assays were performed using the protease domain alone rather than the full-length NS3/4A.

Compound **1** showed sub-nanomolar inhibitory potency against WT NS3/4A protease and maintained nanomolar activity against drug resistant variant D168A and GT3a protease. Similarly, in replicon assays **1** exhibited an excellent potency profile with sub-nanomolar activity against WT HCV (EC₅₀ = 0.14 nM) and low nanomolar activity against drug resistant variants R155K, D168A, and D168V. However, in line with previous reports,³⁶ **1** was highly susceptible to the A156T mutation (EC₅₀ = 238 nM), losing over 1000-fold potency against this variant. Compared to **1**, the P1–P3 macrocyclic analogue **2** exhibited lower inhibitory potency against WT protease and the D168A variant. Also, the inhibitory

activity of **2** against the GT3a protease was considerably lower than that of **1**. However, as we have previously shown,³⁶ **2** displayed a superior potency profile in replicon assays with sub-nanomolar activity against WT HCV (EC_{50} = 0.33 nM) and maintained single digit nanomolar potency against all drug-resistant variants tested. Notably, unlike **1**, compound **2** maintained low nanomolar potency against the A156T variant (EC_{50} = 9.65 nM). Thus, with an improved resistance profile compared to **1**, the P1–P3 macrocyclic analogue **2** is an attractive lead compound for further optimization.

Modifications of P1' and P4 Capping Groups

Initial SAR efforts to optimize lead compound **2** focused on exploring changes at the P1' position and N-terminal capping group. Recent SAR studies of diverse NS3/4A PIs indicate that replacement of the cyclopropylsulfonamide moiety at the P1' position with a slightly more hydrophobic 1-methylcyclopropylsulfonamide improves inhibitor potency in replicon assays.^{43,44} Moreover, changes at the P4 position have been shown to significantly affect inhibitor potency against drug resistant variants, as these groups bind in close proximity to the pivotal drug resistance site Asp168.⁴⁵ For carbamate-linked P4 capping groups, generally bulky hydrophobic moieties are preferred but the size of the group appears to be dependent on the heterocyclic moiety present at the P2 position.³⁵

First, replacing the cyclopropylsulfonamide at the P1' position in **2** with 1-methylcyclopropylsulfonamide provided the analogue **19a**. Compared to the parent compound **2**, **19a** showed slightly better K_i values against WT, D168A and GT3a proteases and exhibited similar or slightly better antiviral potency against WT and drug resistant variants. Next, the *tert*-butyl P4 capping group in both **2** and **19a** was replaced with a larger cyclopentyl moiety, resulting in analogues **22a** and **23a**. Unlike the change at the P1' position, the P4 cyclopentyl modification provided mixed results. Compound **22a** afforded a 2-fold increase in potency than **2** in biochemical assays against WT protease and a slight improvement against the D168A variant, but was equipotent to **2** against GT3a protease. Similarly, in replicon assays **22a** exhibited 2-fold enhanced potency against WT HCV and D168A variant, but showed similar potency as **2** against the R155K and D168V variants. Compound **23a**, with a 1-methylcyclopropylsulfonamide moiety at the P1' position and a cyclopentyl group at the P4 position, exhibited potency profile largely similar to **22a**. Surprisingly, a slight loss in potency was observed against the A156T variant for compounds with a cyclopentyl versus *tert*-butyl capping group. Overall, these minor modifications at the P1' and N-terminal capping regions of inhibitor **2** were tolerated and provided analogues with improved potency profiles.

SAR Exploration of P2 Quinoxaline

Next, SARs at the P2 quinoxaline in compound **2** were explored. Efforts mainly focused on replacing the 3-position ethyl group with diverse functional groups with respect to size and electronic properties. Replacement of the ethyl group in **2** with a smaller methyl group provided analogue **18b**. As expected, reducing the size of the hydrophobic group at this position resulted in improved potency profile. Compound **18b** showed slightly enhanced potency against drug resistant variants in biochemical and antiviral assays, with a notable ~2-fold improvement against the D168V variant (EC_{50} = 3.17 nM). The introduction of 1-

methylcyclopropylsulfonamide moiety at the P1' position afforded inhibitor **19b** with protease inhibitory activity comparable to the parent compound **18b**. However, similar to the 3-ethylquinoxaline analogue (**19a**), compound **19b** demonstrated significant gain in potency in replicon assays. In fact, compared to **2**, **19b** exhibited 2- to 6-fold enhancement in potency against drug resistant variants R155K ($EC_{50} = 0.80$ nM), A156T ($EC_{50} = 1.57$ nM), D168A ($EC_{50} = 2.37$ nM), and D168V ($EC_{50} = 1.6$ nM). Replacement of the *tert*-butyl P4 capping in **18b** and **19b** with a cyclopentyl group, providing **22b** and **23b**, resulted in an increase in WT and D168A inhibitory activity as well as 2- to 3-fold increase in WT replicon potency. Unlike the corresponding 3-ethylquinoxaline analogues (**22a** and **23a**), the 3-methylquinoxaline compounds **22b** and **23b** maintained the excellent potency profile observed for the corresponding *tert*-butyl analogues. Remarkably, with the exception of **18b** (A156T $EC_{50} = 5.95$ nM), all compounds in the 3-methylquinoxaline series display exceptional potency profiles with EC_{50} values below 5 nM against WT and clinically relevant drug resistant variants.

To gain insights into the excellent potency profile observed for the 3-methylquinoxaline series, we determined the X-ray crystal structure of inhibitor **19b** in complex with the WT NS3/4A protease at a resolution of 1.8 Å (Figure 3, Table S3, PDB code: 5VOJ). The WT-**19b** complex structure was compared with the previously reported structures of compound **2** in complex with WT protease and the A156T variant (PDB codes: 5EPN and 5EPY).³⁸ The two WT structures overlap very well, with only minor differences in the S1 and S2 subsites because of modifications in the inhibitor structure. In the WT-**2** crystal structure, the 3-ethyl group at the P2 quinoxaline makes hydrophobic interactions with the hydrocarbon portion of the Arg155 side-chain, while the methylene portion of this group interacts with the side-chain of Ala156. The smaller methyl group at this position in the WT-**19b** structure maintains hydrophobic interactions with Ala156, while minimizing chances of steric clash with a larger side-chain, such as in A156T.

Unlike inhibitor **1**, the P1–P3 macrocyclic analogues retain potency against the A156T variant. Comparison of the WT-**2** and A156T-**2** (PDB code: 5EPY) structures shows subtle changes in inhibitor interactions with the mutant protease.³⁸ In the A156T-**2** structure the P2 quinoxaline largely maintains interactions with the catalytic residues, but the ethyl group is shifted away from Arg155 side chain toward A156T. Moreover, to accommodate a larger Thr side-chain, the Asp168 side chain adopts another conformation, moving away from Arg155. These changes underlie reduced inhibitor potency against the A156T variant, but unlike **1**, inhibitor **2** is able to better accommodate these changes due to a flexible P2 moiety. The 3-methylquinoxaline analogues are more potent against the A156T variant than the corresponding 3-ethylquinoxaline compounds likely due the reduced interactions of the smaller methyl group with the Thr side-chain. Replacing the methyl group with hydrogen at the 3-position of quinoxaline would further reduce interactions with the S2 subsite residues, but could result in a highly flexible P2 moiety, likely destabilizing interactions with the catalytic residues. Thus, a small hydrophobic group at the 3-position of P2 quinoxaline is preferred to maintain favorable interactions with Ala156 and avoid steric clashes with the Thr side-chain in the A156T variant.

The improved potency profile of 3-methylquinoxaline compounds led to exploration of bioisosteric replacements of the 3-methyl group with varied size and electronic properties. To that end, analogues **18c** and **19c** bearing the 3-chloro-7-methoxyquinoxaline at the P2 position were prepared. The protease inhibitory potency profiles of these compounds were excellent and showed improvement against WT, D168A and GT3a over **2**. These potency gains were not only maintained in replicon assays but were more significant, with the only exception of A156T variant. Both compounds **18c** and **19c** were more active than the corresponding 3-methylquinoxaline analogues (**18b** and **19b**) with EC₅₀ values less than 1 nM against WT, R155K and D168V and less than 2 nM against the D168A variant, but experienced about 3- to 6-fold reduction in potency against the A156T variant. However, potency losses against the A156T variant were largely reversed when the P4 *tert*-butyl group in **18c** and **19c** was replaced with a larger cyclopentyl moiety to afford **22c** and **23c**. Similar to the 3-methylquinoxaline compounds, the 3-chloroquinoxaline analogues displayed exceptional potency profiles with EC₅₀ values of less than 5 nM against all drug resistant variants including A156T. These results clearly demonstrate that small hydrophobic groups with weak electron-donating properties at the 3-position of P2 quinoxaline can be replaced with weak electron-withdrawing groups without affecting the overall potency profile.

Next, a larger and strongly electron-withdrawing trifluoromethyl moiety was explored at the 3-position of P2 quinoxaline, leading to inhibitors **18d** and **19d**. This modification, however, resulted in significant potency losses in both biochemical and replicon assays. Compound **18d** was about 2- to 4-fold less active than **2** against WT protease and variants. Analogue **19d** with the 1-methylcyclopropylsulfonamide moiety at the P1' position showed similar trends when compared to the corresponding **19a**. In line with biochemical data, both **18d** and **19d** suffered 2- to 6-fold decrease in replicon potency against WT and drug resistant variants, though **19d** maintained relatively good potency profile. In contrast to the results in previous series, the introduction of the larger cyclopentyl P4 capping group, as in **22d** and **23d**, was detrimental to replicon potency, particularly against the A156T variant. Moreover, compounds in the 3-(trifluoromethyl)quinoxaline series were among the least active against the GT3a protease in biochemical assays. These results indicate that strong electron-withdrawing groups at the 3-position of the P2 quinoxaline may be detrimental to potency. However, a recent SAR study indicates that PIs incorporating the 3-(trifluoromethyl)quinoxaline can be optimized with modifications at the 7-position of quinoxaline in combination with changes at the P1–P3 macrocycle and P4 capping group.⁴⁶

In the absence of a co-crystal structure, the lower inhibitory potencies of compounds in the 3-(trifluoromethyl)quinoxaline series against WT protease could not be explained by molecular modeling, which suggested a similar binding conformation of the P2 quinoxaline in **18d** as observed for **2** (Figure 4A). Perhaps there are repulsive interactions between trifluoromethyl moiety and the side chain of Asp168, and/or the strong electron-withdrawing effect may weaken the overall interactions of the P2 quinoxaline with the catalytic residues. Potency losses against resistant variants may also result from the larger size of the trifluoromethyl moiety, which is comparable to that of an ethyl group, though both have different topographical shapes.⁴⁷

To isolate the effects of larger size versus electronic properties on potency, inhibitors **18e** and **19e** with the larger isopropyl group at the 3-position of the P2 quinoxaline were designed and evaluated. These compounds showed WT protease inhibitory activity similar to the corresponding 3-ethylquinoxaline analogues (**2** and **19a**), but experienced 2- to 4-fold reduced activity against the D168A variant. A broader reduction in potency was observed for both **18e** and **19e** in replicon assays against WT and drug resistant variants. The cyclopentyl P4 group in analogues **22e** and **23e** slightly improved biochemical and replicon potency against WT and D168A variants, but was largely unfavorable to replicon potency against R155K and A156T variants. This trend is broadly similar to the results observed with the 3-(trifluoromethyl)quinoxaline series, indicating that both electronic properties and size of the group at the 3-position of P2 quinoxaline are important for maintaining potency against drug resistant variants. Modeling indicated that compared to **2** the P2 quinoxaline moiety in **18e** has to shift away from the catalytic triad in order to accommodate the larger isopropyl group thereby weakening critical stacking interactions with His57 (Figure 4B). Overall, SAR data from the 3-isopropyl- and 3-(trifluoromethyl)-quinoxaline series supports the hypothesis that large substituents at the 3-position of P2 quinoxaline have detrimental effect on inhibitor potency against drug resistant variants.

These findings were further reinforced by the results obtained for the 3-(thiophen-2-yl)quinoxaline analogues **18f** and **22f**. Based on molecular modeling, the large thiophene moiety in these compounds was expected to make extensive interactions with the residues Arg155 and Ala156, resulting in improved potency against WT protease. However, mutations at these positions as well as at Asp168 would cause significant potency losses, as these residues are crucial for efficient inhibitor binding. As expected, compound **18f** (a previously reported NS3/4A PI incorrectly labeled as ABT-450)^{19,48} showed a 3-fold enhancement in WT biochemical potency but was dramatically less active against the D168A variant, losing over 1800-fold potency. Similarly, in replicon assays analogue **18f** showed considerably reduced potency against all drug resistant variants with losses ranging from 20- to 250-fold compared to WT (Table S1 and S2). The cyclopentyl P4 analogue **22f** also experienced large potency losses against the variants, albeit to a lesser extent than **18f**. Thus inhibitors with large groups at the 3-position of P2 quinoxaline are highly susceptible to mutations at residues Arg155, Ala156 and Asp168, leading to poor resistance profiles.

The X-ray crystal structure of inhibitor **18f** in complex with WT NS3/4A protease was determined at a resolution of 1.9 Å, providing insights into the binding modes of P2 quinoxaline with a larger thiophene substituent at the 3-position (Figure 5, Table S3, PDB code: 5VP9). Comparison of the WT-**18f** and WT-**2** crystal structures showed significant differences in the interactions of quinoxaline moieties with the catalytic triad and S2 subsite residues. As predicted, the quinoxaline moiety in WT-**18f** structure is shifted toward the active site to accommodate the larger thiophene substituent. The thiophene ring makes extensive interactions with residues in the S2 subsite, including cation- π interactions with Arg155, likely contributing to the improved potency against the WT protease. As this Arg155 conformation is stabilized by electrostatic interactions with Asp168, mutations at either residue would disrupt inhibitor binding by loss of direct interactions as well as indirect structural effects. In addition, the A156T mutation would result in a steric clash with

the thiophene ring, as reflected in the antiviral data for this variant. These biochemical and structural findings are in line with previous studies that show inhibitors that are dependent on extensive interactions with the S2 subsite residues for potency are highly susceptible to mutations at residues Arg155, Ala156 and Asp168.

As compounds **18f** and **22f** lacked the C-7 substituent at the P2 quinoxaline, analogues **18g** and **22g** were prepared to investigate the effect of this group on inhibitor potency. Compared to **2**, analogue **18g** experienced about 2-fold decrease in biochemical potency and only minor loss in replicon potency against WT and drug resistant variants. The P4 cyclopentyl analogue **22g** resulted in about 2-fold reduced potency compared to the corresponding compound **22a**. Thus removal of the C-7 methoxy group has minimal effect on inhibitor potency. The slightly reduced potency of **18g** and **22g** is likely due to the reduced hydrophobic interactions with the aromatic ring of Tyr56 and the methylene portion of His57 of the catalytic triad. In contrast, the observed potency losses against resistant variants for the 3-(thiophen-2-yl)quinoxaline compounds most likely result from loss of interactions of the 2-thiophene moiety with the S2 subsite residues of the protease.

Effects of P2 Substituent Size and Flexibility

Taken together, our SAR results indicate that resistance profiles of compound **2** and analogues are strongly influenced by the substituent at the 3-position of P2 quinoxaline and *N*-terminal capping group. While all PIs showed reduced potency against drug resistance variants in both enzyme inhibition and replicon assays, fold potency losses varied significantly depending on the substituents at the 3-position of P2 quinoxaline. To evaluate susceptibility to the clinically important D168A variant, to which all current NS3/4A PIs are susceptible, potencies were normalized to WT for PIs with the same P4 capping groups (Figure 6). Fold changes in *K_i* against the D168A protease variant for PIs with the same P1' and P4 capping groups largely trended with the size of the substituent at the 3-position of P2 quinoxaline, with the exception of trifluoromethyl compounds. Losses in potency were significantly higher for compounds with the larger 2-thiophene substituent at the P2 quinoxaline. These results strongly support using the substrate envelope model to reduce direct inhibitor interactions in the S2 subsite, thereby reducing inhibitor susceptibility to drug resistance.

As we and others have shown,^{31–33,35} the reduced potencies of NS3/4A PIs against drug resistant variants R155K, A156T, and D168A/V mainly result from disruption of the electrostatic interactions between Arg155 and Asp168. Compared to **1**, compound **2** and most analogues incorporating flexible P2 quinoxaline showed lower fold-changes in potency against these variants (Table S1 and S2). In these P1–P3 macrocyclic PIs the conformational flexibility of the P2 allows this moiety to adapt to the structural changes caused by mutations at Arg155, Ala156 and Asp168, resulting in better resistance profiles. Potency losses were higher for compound **1** because constraint imposed by the macrocycle does not allow the P2 moiety to adapt to the structural changes resulting from these mutations. Compound **1** and similar P2–P4 macrocyclic PIs, such as voxilaprevir and glecaprevir, are likely to be more susceptible to mutations that cause significant structural changes in the protease active site. However, the P1–P3 macrocyclic compounds reported here, as well as

those reported in patent literature that incorporate similar flexible P2 quinoxaline moieties,⁴⁹ are likely to be more effective against clinically relevant drug resistant variants. More broadly, combining the substrate envelope model with optimal conformational flexibility provides a rational approach to design NS3/4A PIs with improved resistance profiles.

CONCLUSIONS

Drug resistance is a major problem across all DAA classes targeting HCV. As new therapies are developed the potential for drug resistance must be minimized at the outset of inhibitor design. The substrate envelope model provides a rational approach to design robust NS3/4A PIs with improved resistance profiles. Our SAR findings support the hypothesis that reducing PI interactions with residues in the S2 subsite leads to inhibitors with exceptional potency and resistance profiles. Specifically, the P1–P3 macrocyclic inhibitors incorporating flexible P2 quinoxaline moieties bearing small hydrophobic groups at the 3-position maintain excellent potency in both enzymatic and antiviral assays against drug resistant variants. While these inhibitors protrude from the substrate envelope, they leverage interactions with the essential catalytic triad residues and avoid direct contacts with residues that can mutate to confer resistance. Moreover, conformational flexibility at the P2 moiety is essential to efficiently accommodate structural changes due to mutations in the S2 pocket in order to avoid resistance. These insights provide strategies for iterative rounds of inhibitor design with the paradigm that designing inhibitors with flexible P2 quinoxalines, leveraging evolutionarily constrained areas in the protease active site and expanding into the substrate envelope may provide inhibitors that are robust against drug resistant variants.

EXPERIMENTAL SECTION

General

All reactions were performed in oven-dried round bottomed or modified Schlenk flasks fitted with rubber septa under argon atmosphere, unless otherwise noted. All reagents and solvents, including anhydrous solvents, were purchased from commercial sources and used as received. Flash column chromatography was performed using silica gel (230–400 mesh, EMD Millipore). Thin-layer chromatography (TLC) was performed using silica gel (60 F-254) coated aluminum plates (EMD Millipore), and spots were visualized by exposure to ultraviolet light (UV), exposure to iodine adsorbed on silica gel, and/or exposure to an acidic solution of *p*-anisaldehyde (anisaldehyde) followed by brief heating. ¹H NMR and ¹³C NMR spectra were acquired on Varian Mercury 400 MHz and Bruker Avance III HD 500 MHz NMR instruments. Chemical shifts are reported in ppm (δ scale) with the residual solvent signal used as reference and coupling constant (*J*) values are reported in hertz (Hz). Data are presented as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet), coupling constant in Hz, and integration. High-resolution mass spectra (HRMS) were recorded on a Thermo Scientific Orbitrap Velos Pro mass spectrometer coupled with a Thermo Scientific Accela 1250 UPLC and an autosampler using electrospray ionization (ESI) in the positive mode. The purity of final compounds was determined by analytical HPLC and was found to be 95% pure. HPLC was performed on a Waters Alliance 2690 system equipped with a Waters

2996 photodiode array detector and an autosampler under the following conditions: column, Phenomenex Luna-2 RP-C18 (5 μ m, 4.6 $\times$ 250 mm, 120 Å, Torrance, CA); solvent A, H₂O containing 0.1% formic acid (FA), solvent B, CH₃CN containing 0.1% FA; gradient, 50% B to 100% B over 15 min followed by 100% B over 5 min; injection volume, 10 μ L; flow rate, 1 mL/min. Retention times and purity data for each target compound are provided in the experimental section.

Typical procedures for the synthesis of protease inhibitors using Method A

1-(*tert*-Butyl) 2-methyl (2*S*,4*R*)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (9a)—A solution of 3-ethyl-7-methoxyquinoxalin-2-one **8a** (3.0 g, 14.7 mmol) in anhydrous NMP (45 mL) was treated with Cs₂CO₃ (7.40 g, 22.7 mmol). After stirring the reaction mixture at room temperature for 15 min, proline derivative **3** (6.20 g, 13.3 mmol) was added in one portion. The reaction mixture was heated to 55 °C, stirred for 4 h, and then another portion of proline derivative **3** (0.48 g, 1.0 mmol) was added. The resulting reaction mixture was stirred at 55 °C for an additional 2 h, cooled to room temperature, quenched with aqueous 1 N HCl solution (150 mL), and extracted with EtOAc (300 mL). The organic fraction was washed successively with saturated aqueous NaHCO₃ and NaCl (150 mL each), dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by flash column chromatography using 15–30% EtOAc/hexanes as the eluent to provide **9a** (5.50 g, 87%) as a white foamy solid. ¹H NMR (400 MHz, CDCl₃) (mixture of rotamers, major rotamer) δ 7.85 (d, *J* = 9.0 Hz, 1 H), 7.18 (m, 1H), 7.11 (d, *J* = 2.8 Hz, 1 H), 5.73 (br s, 1 H), 4.47 (t, *J* = 8.0 Hz, 1 H), 3.98–3.86 (m, 5 H), 3.78 (s, 3 H), 2.92 (q, *J* = 7.2 Hz, 2 H), 2.68–2.60 (m, 1 H), 2.43–2.36 (m, 1 H), 1.43 (s, 9 H), 1.31 (t, *J* = 7.2 Hz, 3 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 173.56, 160.59, 155.38, 154.02, 148.95, 141.26, 134.12, 129.07, 119.02, 106.11, 80.76, 73.81, 58.43, 55.93, 52.73, 52.40, 36.88, 28.47, 26.68, 11.97 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₂H₃₀N₃O₆, 432.2129; found 432.2135.

1-(*tert*-Butyl) 2-methyl (2*S*,4*R*)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (9d)—The same procedure was used as described above for compound **9a**. 7-methoxy-3-(trifluoromethyl)quinoxalin-2(1*H*)-one **8d** (4.76 g, 19.5 mmol) in NMP (65 mL) was treated with Cs₂CO₃ (9.80 g, 30.0 mmol) and proline derivative **3** (9.0 g, 19.3 mmol) to provide **9d** (6.50 g, 71%) as a pale yellow foamy solid. ¹H NMR (500 MHz, CDCl₃) (mixture of rotamers, major rotamer) δ 7.77 (d, *J* = 9.0 Hz, 1 H), 7.48–7.43 (m, 2 H), 5.76 (br s, 1 H), 4.50 (t, *J* = 8.0 Hz, 1 H), 3.97–3.91 (m, 5 H), 3.78 (s, 3 H), 2.69–2.64 (m, 1 H), 2.41–2.34 (m, 1 H), 1.42 (s, 9 H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 173.43, 159.58, 153.98, 152.11, 138.39, 137.22, 127.99, 125.73, 120.70 (q, *J* = 273.4 Hz), 107.64, 80.69, 74.62, 58.27, 56.02, 52.32, 52.11, 36.70, 28.34 ppm; ¹⁹F NMR (470 MHz, CDCl₃); –67.73 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₅F₃N₃O₆, 472.1690; found 472.1689.

Methyl (2*S*,4*R*)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)non-8-enoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12a)—A solution of ester **9a** (4.80 g, 11.1 mmol) in anhydrous CH₂Cl₂ (30 mL) was treated with a solution of 4 N HCl in 1,4-dioxane (30 mL). After stirring the reaction mixture at room temperature for 3 h,

solvents were evaporated under reduced pressure, and the residue was dried under high vacuum. The pale yellow solid was triturated with diethyl ether (3 × 30 mL) and dried under high vacuum to yield the amine salt **10a** (4.0 g, 98%) as an off-white powder.

A mixture of amine salt **10a** (4.0 g, 10.9 mmol) and (*S*)-2-((*tert*-butoxycarbonyl)amino)non-8-enoic acid **11** (3.0 g, 11.1 mmol) in anhydrous DMF (60 mL) was treated with DIEA (7.30 mL, 44.2 mmol) and HATU (6.35 g, 16.7 mmol). The resulting reaction mixture was stirred at room temperature for 4 h, then diluted with EtOAc (400 mL), and washed successively with aqueous 0.5 N HCl, saturated aqueous NaHCO₃, and saturated aqueous NaCl (250 mL each). The organic portion was dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 20–30% EtOAc/hexanes as the eluent to provide **12a** (5.50 g, 86%) as a white foamy solid. ¹H NMR (400 MHz, CDCl₃) (mixture of rotamers, major rotamer) δ 7.86 (d, *J* = 8.8 Hz, 1 H), 7.20 (dd, *J* = 9.2, 2.8 Hz, 1 H), 7.12 (d, *J* = 2.8 Hz, 1 H), 5.87–5.75 (m, 2 H), 5.20 (d, *J* = 8.4 Hz, 1 H), 5.02–4.92 (m, 2 H), 4.73 (t, *J* = 8.4 Hz, 1 H), 4.38 (q, *J* = 7.2 Hz, 1 H), 4.17 (d, *J* = 12.0 Hz, 1 H), 4.06 (dd, *J* = 11.6, 4.4 Hz, 1 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 2.90 (q, *J* = 7.6 Hz, 2 H), 2.69–2.64 (m, 1 H), 2.41–2.34 (m, 1 H), 2.05 (app q, *J* = 6.8 Hz, 2 H), 1.82–1.74 (m, 1 H), 1.63–1.56 (m, 1 H), 1.45–1.25 (m, 18 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 172.34, 171.96, 160.61, 155.61, 155.13, 148.95, 141.08, 139.18, 129.22, 119.08, 114.58, 106.14, 79.84, 74.48, 58.19, 55.91, 52.88, 52.67, 52.05, 35.16, 33.88, 32.88, 29.14, 28.96, 28.46, 26.52, 24.92, 11.86 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₄₅N₄O₇ 585.3283; found 585.3286.

Methyl (2*S*,4*R*)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)non-8-enoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12d**)**

—The same procedure was used as described above for compound **12a**. Compound **9d** (6.0 g, 12.7 mmol) was treated with 4 N HCl (40 mL) to afford amine salt **10d** (5.10 g, 12.5 mmol), which was coupled with acid **11** (3.80 g, 14.0 mmol) using DIEA (9.25 mL, 56.0 mmol) and HATU (7.60 g, 20.0 mmol) to provide **12d** (6.40 g, 81%) as a pale yellow foamy solid. ¹H NMR (500 MHz, CDCl₃) (mixture of rotamers, major rotamer) δ 7.78 (d, *J* = 9.0 Hz, 1 H), 7.48 (dd, *J* = 9.0, 2.5 Hz, 1 H), 7.44 (d, *J* = 2.5 Hz, 1 H), 5.86 (br s, 1 H), 5.84–5.78 (m, 1 H), 5.18 (d, *J* = 9.0 Hz, 1 H), 5.01–4.92 (m, 2 H), 4.75 (t, *J* = 8.0 Hz, 1 H), 4.35 (q, *J* = 7.5 Hz, 1 H), 4.19 (d, *J* = 12.0 Hz, 1 H), 4.08 (dd, *J* = 11.5, 4.5 Hz, 1 H), 3.95 (s, 3 H), 3.78 (s, 3 H), 2.70–2.65 (m, 1 H), 2.41–2.35 (m, 1 H), 2.04 (app q, *J* = 7.0 Hz, 2 H), 1.80–1.75 (m, 1 H), 1.60–1.54 (m, 1 H), 1.45–1.28 (m, 15 H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 172.10, 171.60, 159.99, 155.37, 151.78, 138.98, 138.41, 136.93, 134.40 (q, *J* = 36.3 Hz), 127.85, 125.66, 120.53 (q, *J* = 273.4 Hz), 114.33, 107.54, 79.58, 75.05, 57.83, 55.91, 52.44, 52.33, 51.75, 34.77, 33.65, 32.70, 28.91, 28.73, 28.18, 24.70 ppm; ¹⁹F NMR (470 MHz, CDCl₃); –67.73 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₀H₄₀F₃N₄O₇, 625.2844; found 625.2844.

***tert*-Butyl ((*S*)-1-((2*S*,4*R*)-2-(((1*R*,2*S*)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (**16a**)**—A solution of ester **12a** (5.86 g, 10.0 mmol) in THF-H₂O mixture (1:1, 140 mL) was treated with LiOH·H₂O

(1.40 g, 33.4 mmol). The resulting reaction mixture was stirred at room temperature for 24 h. The reaction mixture was cooled to ~5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl (~ 200 mL), and extracted with EtOAc (2 × 400 mL). The organic portions were washed separately with saturated aqueous NaCl (200 mL), dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl₃ (50 mL), concentrated under reduced pressure, and the residue was dried under high vacuum overnight to yield the acid **13a** (5.70 g, 100%) as a white foamy solid.

A mixture of acid **13a** (2.10 g, 3.7 mmol) and amine salt **14**⁴² (1.20 g, 4.5 mmol) in anhydrous DMF (35 mL) was treated with DIEA (2.43 mL, 14.7 mmol) and HATU (2.1 g, 5.5 mmol). The resulting reaction mixture was stirred at room temperature for 2.5 h, then diluted with EtOAc (300 mL) and washed successively with aqueous 0.5 N HCl, saturated aqueous NaHCO₃, and saturated aqueous NaCl (200 mL each). The organic portion was dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 50–70% EtOAc/hexanes as the eluent to provide the bisolefin compound **16a** (2.50 g, 86%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.24 (s, 1 H), 7.84 (d, *J* = 8.8 Hz, 1 H), 7.18 (dd, *J* = 8.8, 2.4 Hz, 1 H), 7.13 (d, *J* = 2.8 Hz, 1 H), 7.04 (s, 1 H), 5.91 (br s, 1 H), 5.85–5.73 (m, 2 H), 5.32 (d, *J* = 8.4 Hz, 1 H), 5.27 (d, *J* = 17.2 Hz, 1 H), 5.14 (d, *J* = 11.2 Hz, 1 H), 5.01–4.90 (m, 2 H), 4.47 (t, *J* = 7.6 Hz, 1 H), 4.38–4.33 (m, 1 H), 4.20 (d, *J* = 11.6 Hz, 1 H), 4.02 (dd, *J* = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.96–2.84 (m, 3 H), 2.56–2.51 (m, 2 H), 2.11 (q, *J* = 8.8 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.74–1.54 (m, 2 H), 1.47–1.10 (m, 21 H), 1.08–1.03 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 174.09, 172.58, 168.69, 160.54, 155.89, 154.99, 148.88, 140.95, 139.07, 134.69, 132.71, 129.45, 119.02, 118.77, 114.67, 106.13, 80.0, 74.66, 60.61, 55.91, 53.42, 52.62, 41.83, 35.46, 34.47, 33.89, 32.40, 31.39, 28.98, 28.89, 28.47, 26.68, 25.47, 23.83, 11.85, 6.68, 6.26 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₉H₅₅N₆O₉S, 783.3746; found 783.3734.

***tert*-Butyl ((*S*)-1-((2*S*,4*R*)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-2-(((1*R*,2*S*)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (**17a**)**—

The same procedure was used as described above for compound **16a**. Acid **13a** (1.50 g, 2.6 mmol) was coupled with amine salt **15**⁴³ (0.90 g, 3.2 mmol) using DIEA (1.75 mL, 10.6 mmol) and HATU (1.50 g, 3.9 mmol) to provide the bisolefin compound **17a** (1.75 g, 84%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.02 (s, 1 H), 7.84 (d, *J* = 9.2 Hz, 1 H), 7.19 (dd, *J* = 8.8, 2.8 Hz, 1 H), 7.13 (d, *J* = 2.8 Hz, 1 H), 7.06 (s, 1 H), 5.90 (br s, 1 H), 5.83–5.73 (m, 2 H), 5.37 (d, *J* = 9.2 Hz, 1 H), 5.27 (d, *J* = 17.2 Hz, 1 H), 5.14 (d, *J* = 10.8 Hz, 1 H), 5.98 (dd, *J* = 17.2, 1.6 Hz, 1 H), 4.92 (dd, *J* = 10.4, 1.2 Hz, 1 H), 4.48 (t, *J* = 8.0 Hz, 1 H), 4.39–4.33 (m, 1 H), 4.16 (d, *J* = 12.0 Hz, 1 H), 4.02 (dd, *J* = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.89 (q, *J* = 7.6 Hz, 2 H), 2.57–2.50 (m, 2 H), 2.12 (q, *J* = 8.8 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.75–1.58 (m, 4 H), 1.49 (s, 3 H), 1.45–1.18 (m, 19 H), 0.93–0.79 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 173.79, 172.41, 167.51, 160.31, 155.71, 154.76, 148.63, 140.73, 138.85, 134.41, 132.60, 129.18, 118.80, 118.54, 114.41, 105.89, 79.74, 74.42, 60.36, 55.68, 53.17, 52.43, 41.71, 36.56, 35.23, 34.22, 33.64, 32.19, 28.70, 28.67, 28.25, 26.43, 25.35, 23.49, 18.37, 14.27, 13.29, 11.64 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₄₀H₅₇N₆O₉S, 797.3902; found 797.3887.

***tert*-Butyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-14*a*-((cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (2)**—A degassed solution of bis-olefin **16a** (1.40 g, 1.8 mmol) in 1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1b catalyst (0.150 g, 0.20 mmol) was added in two portions over 10 min. The resulting reaction mixture was heated to 70 °C and stirred for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by flash chromatography using 50–80% EtOAc/hexanes as the eluent to yield the P1–P3 macrocyclic product **2** (0.72 g, 53%) as an off-white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.28 (s, 1 H), 7.84 (d, *J* = 9.6 Hz, 1 H), 7.20–7.15 (m, 2 H), 6.91 (s, 1 H), 5.90 (br s, 1 H), 5.69 (q, *J* = 8.8 Hz, 1 H), 5.14 (d, *J* = 7.6 Hz, 1 H), 4.96 (t, *J* = 9.2 Hz, 1 H), 4.59 (t, *J* = 7.6 Hz, 1 H), 4.49 (d, *J* = 11.6 Hz, 1 H), 4.30–4.24 (m, 1 H), 4.02 (dd, *J* = 10.8, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.85 (m, 3 H), 2.70–2.51 (m, 3 H), 2.31 (q, *J* = 8.8 Hz, 1 H), 1.93–1.64 (m, 2 H), 1.60–1.05 (m, 24 H), 0.95–0.89 (m, 1 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.15, 173.28, 168.02, 160.29, 155.00, 154.90, 148.66, 140.88, 136.31, 134.28, 128.90, 124.47, 118.82, 105.91, 79.84, 74.68, 59.45, 55.72, 53.08, 51.92, 44.57, 34.65, 32.81, 31.01, 29.70, 28.14, 27.11, 27.16, 26.31, 26.06, 22.16, 20.92, 11.56, 6.67, 6.12 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₅₁N₆O₉S, 755.3433; found 755.3410. Anal. HPLC: *t*_R 14.23 min, purity 97%.

***tert*-Butyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-14*a*-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (19*a*)**—The same procedure was used as described above for compound **2**. Bis-olefin **17a** (1.45 g, 1.8 mmol) was treated with Zhan 1b catalyst (0.150 g, 0.20 mmol) in 1,2-DCE (300 mL) to afford the P1–P3 macrocyclic product **19a** (1.0 g, 71%) as an off-white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.16 (s, 1 H), 7.82 (d, *J* = 10.0 Hz, 1 H), 7.18–7.15 (m, 2 H), 6.94 (s, 1 H), 5.90 (br s, 1 H), 5.69 (q, *J* = 9.2 Hz, 1 H), 5.16 (d, *J* = 8.0 Hz, 1 H), 4.99 (t, *J* = 9.2 Hz, 1 H), 4.59 (t, *J* = 8.0 Hz, 1 H), 4.49 (d, *J* = 11.6 Hz, 1 H), 4.30–4.25 (m, 1 H), 4.04 (dd, *J* = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.87 (q, *J* = 7.6 Hz, 2 H), 2.70–2.51 (m, 3 H), 2.33 (q, *J* = 8.0 Hz, 1 H), 1.92–1.68 (m, 4 H), 1.60–1.15 (m, 24 H), 0.85–0.78 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.19, 173.24, 167.0, 160.23, 154.99, 154.88, 148.73, 140.84, 136.26, 134.25, 129.03, 124.89, 118.72, 105.92, 79.84, 74.67, 59.48, 55.72, 53.11, 51.92, 44.71, 36.43, 34.68, 32.80, 29.62, 28.14, 27.09, 26.38, 26.12, 22.19, 20.93, 18.17, 14.51, 12.50, 11.54 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₈H₅₃N₆O₉S, 769.3589; found 769.3561. Anal. HPLC: *t*_R 15.01 min, purity 99%.

Cyclopentyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-14*a*-((cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (22*a*)—Compound **2** (0.40 g, 0.53 mmol) was treated with a solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 3 h,

then concentrated under reduced pressure, and the residue was dried under high vacuum. The off-white solid was triturated with diethyl ether (3 × 10 mL) and dried under high vacuum to yield the amine salt **20a** (0.37 g, 100%) as a white powder.

A solution of the above amine salt **20a** (0.37 g, 0.53 mmol) in anhydrous CH₃CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and *N*-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction mixture was stirred at room temperature for 36 h, then concentrated under reduced pressure and dried under high vacuum. The residue was purified by flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the target compound **22a** (0.32 g, 79%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.29 (s, 1 H), 7.83 (d, *J* = 9.6 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.94 (s, 1 H), 5.93 (br s, 1 H), 5.70 (q, *J* = 8.8 Hz, 1 H), 5.26 (d, *J* = 8.0 Hz, 1 H), 4.96 (t, *J* = 8.4 Hz, 1 H), 4.86–4.82 (m, 1 H), 4.60 (t, *J* = 7.6 Hz, 1 H), 4.45 (d, *J* = 11.2 Hz, 1 H), 4.34–4.28 (m, 1 H), 4.03 (dd, *J* = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.85 (m, 3 H), 2.70–2.48 (m, 3 H), 2.30 (q, *J* = 8.8 Hz, 1 H), 1.93–1.23 (m, 23 H), 1.15–1.06 (m, 2 H), 0.96–0.88 (m, 1 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.18, 173.03, 168.04, 160.28, 155.65, 154.93, 148.78, 140.90, 136.27, 134.20, 128.92, 124.46, 118.80, 105.92, 77.87, 74.55, 59.47, 55.72, 53.01, 52.17, 44.54, 34.58, 32.72, 32.63, 32.59, 31.01, 29.70, 27.14, 27.05, 26.40, 26.05, 23.56, 22.16, 20.90, 11.61, 6.67, 6.12 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₈H₅₁N₆O₉S, 767.3433; found 767.3408. Anal. HPLC: *t*_R 14.50 min, purity 98%.

Cyclopentyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-2-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (23a**)**—The same procedure was used as described above for compound **22a**. Compound **19a** (0.40 g, 0.52 mmol) was treated with 4 N HCl in 1,4-dioxane (10 mL) to yield the amine salt **21a**, which was treated with DIEA (0.35 mL, 2.1 mmol) and *N*-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide the target compound **23a** (0.30 g, 74%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.17 (s, 1 H), 7.81 (d, *J* = 9.6 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.93 (s, 1 H), 5.92 (br s, 1 H), 5.70 (q, *J* = 9.2 Hz, 1 H), 5.26 (d, *J* = 7.6 Hz, 1 H), 4.99 (t, *J* = 9.6 Hz, 1 H), 4.86–4.81 (m, 1 H), 4.59 (t, *J* = 7.6 Hz, 1 H), 4.45 (d, *J* = 11.2 Hz, 1 H), 4.34–4.28 (m, 1 H), 4.04 (dd, *J* = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.87 (q, *J* = 7.2 Hz, 2 H), 2.70–2.48 (m, 3 H), 2.32 (q, *J* = 8.8 Hz, 1 H), 1.92–1.23 (m, 27 H), 0.85–0.78 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.21, 172.99, 166.98, 160.22, 155.63, 154.90, 148.84, 140.85, 136.22, 134.36, 129.05, 124.88, 118.70, 105.93, 77.86, 74.54, 59.51, 55.71, 53.05, 52.16, 44.70, 36.43, 34.61, 32.72, 32.64, 32.58, 29.63, 27.13, 27.06, 26.47, 26.12, 23.56, 22.18, 20.94, 18.17, 14.49, 12.50, 11.59 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₉H₅₃N₆O₉S, 781.3589; found 781.3561. Anal. HPLC: *t*_R 15.25 min, purity 99%.

Typical procedures for the synthesis of protease inhibitors using Method B

Ethyl (1*R*,2*S*)-1-((2*S*,4*R*)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)non-8-enoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-carboxylate (25d**)**—A solution of ester **12d**

(6.40 g, 10.25 mmol) in THF-H₂O (1:1 mixture, 140 mL) was treated with LiOH·H₂O (1.38 g, 32.0 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then cooled to ~5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl (~200 mL), and extracted with EtOAc (2 × 500 mL). The organic portions were washed separately with saturated aqueous NaCl (250 mL), dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl₃ (50 mL), concentrated under reduced pressure, and the residue was dried under high vacuum to yield the acid **13d** (6.12 g, 98%) as a pale yellow foamy solid.

A solution of acid **13d** (6.12 g, 10.0 mmol) and amine salt **24** (2.50 g, 13.0 mmol) in anhydrous CH₂Cl₂ (100 mL) was treated with DIEA (9.10 mL, 55.0 mmol), HATU (5.30 g, 14.0 mmol) and DMAP (0.60 g, 4.9 mmol). The resulting reaction mixture was stirred at room temperature for 14 h, then diluted with EtOAc (500 mL), and washed successively with aqueous 1.0 N HCl, saturated aqueous NaHCO₃, and saturated aqueous NaCl (250 mL each). The organic portion was dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 25–35% EtOAc/hexanes as the eluent to provide the bisolefin compound **25d** (6.54 g, 87%) as a pale yellow foamy solid. ¹H NMR (500 MHz, CDCl₃) (mixture of rotamers, major rotamer) δ 7.78 (d, *J* = 9.2 Hz, 1 H), 7.53 (br s, 1 H), 7.47 (dd, *J* = 9.2, 2.8 Hz, 1 H), 7.43 (d, *J* = 2.4 Hz, 1 H), 5.88 (br s, 1 H), 5.81–5.70 (m, 2 H), 5.30 (dd, *J* = 16.8, 0.8 Hz, 1 H), 5.14–5.10 (m, 2 H), 5.01–4.89 (m, 2 H), 4.79 (dd, *J* = 14.0, 5.6 Hz, 1 H), 4.35–4.29 (m, 1 H), 4.21–4.08 (m, 3 H), 3.94 (s, 3 H), 2.90–2.82 (m, 1 H), 2.48–2.38 (m, 1 H), 2.16 (q, *J* = 9.0 Hz, 1 H), 2.04–1.98 (m, 2 H), 1.86 (dd, *J* = 8.0, 5.2 Hz, 1 H), 1.66–1.52 (m, 2 H), 1.46 (dd, *J* = 9.6, 5.6 Hz, 1 H), 1.43–1.21 (m, 19 H) ppm; ¹³C NMR (125 MHz, CDCl₃) δ 173.02, 171.00, 169.87, 159.62, 155.52, 152.03, 138.92, 138.48, 137.16, 133.66, 128.02, 125.73, 120.72 (q, *J* = 273.6 Hz), 118.08, 114.52, 107.66, 79.98, 75.26, 61.40, 58.41, 56.02, 52.58, 52.43, 40.14, 33.89, 33.77, 32.76, 32.62, 28.97, 28.78, 28.31, 25.18, 23.11, 14.48 ppm; ¹⁹F NMR (470 MHz, CDCl₃); –67.77 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₄₉F₃N₅O₈, 748.3528; found 748.3514.

Ethyl (2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-6-((*tert*-butoxycarbonyl)amino)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16atetradecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14*a*(5*H*)-carboxylate (26d**)**—A degassed solution of bis-olefin **25d** (1.50 g, 2.0 mmol) in 1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1b catalyst (0.150 g, 0.20 mmol) was added in two portions over 10 min. The resulting mixture was heated to 70 °C and stirred for 5 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by flash chromatography using 25–35% EtOAc/hexanes as the eluent to yield the P1–P3 macrocyclic product **26d** (1.0 g, 70%) as an off-white foamy solid. ¹H NMR (400 MHz, CDCl₃) δ 7.77 (d, *J* = 8.8 Hz, 1 H), 7.47 (dd, *J* = 8.8, 2.8 Hz, 1 H), 7.44 (d, *J* = 2.4 Hz, 1 H), 7.03 (br s, 1 H), 5.84–5.80 (m, 1 H), 5.56–5.49 (m, 1 H), 5.32–5.22 (m, 2 H), 4.92 (q, *J* = 4.4 Hz, 1 H), 4.49 (t, *J* = 7.6 Hz, 1 H), 4.24–4.05 (m, 4 H), 3.95 (s, 3 H), 3.05–2.99 (m, 1 H), 2.41–2.35 (m, 1 H), 2.24–2.14 (m, 3 H), 1.93–1.86 (m, 2 H), 1.66–1.60 (m, 1 H), 1.55 (dd, *J* = 9.6, 5.2 Hz, 1 H), 1.46–1.20 (m, 18 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 172.81,

171.95, 169.74, 159.69, 155.21, 152.20, 138.56, 137.25, 134.50, 128.08, 125.91, 125.84, 120.80 (q, $J = 276$ Hz), 107.73, 80.04, 75.42, 61.50, 58.08, 56.13, 52.21, 51.39, 41.36, 32.16, 31.77, 28.45, 28.10, 28.02, 26.37, 25.74, 23.70, 22.57, 14.72 ppm; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{35}H_{45}F_3N_5O_8$, 720.3215; found 720.3203.

***tert*-Butyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-14a-((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (18d)**—A solution of ester **26d** (1.0 g, 1.4 mmol) in THF-MeOH-H₂O (1:1:1 mixture, 20 mL) was treated with LiOH·H₂O (0.18 g, 4.2 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then cooled to ~5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl, and extracted with EtOAc (2 × 150 mL). The organic portions were washed separately with saturated aqueous NaCl (100 mL), dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The gummy residue was dissolved in CHCl₃ (10 mL), concentrated under reduced pressure, and the residue was dried under high vacuum to yield the acid **27d** (0.95 g, 98%) as a pale yellow foamy solid.

A mixture of acid **27d** (0.40 g, 0.58 mmol) and CDI (0.131 g, 0.81 mmol) in anhydrous THF (8 mL) was heated at reflux for 1.5 h. The solution was cooled to room temperature and slowly added to a solution of cyclopropanesulfonamide **28** (0.10 g, 0.82 mmol) in anhydrous THF (4 mL) followed by DBU (0.12 mL, 0.81 mmol). The resulting reaction mixture was stirred at room temperature for 24 h, then quenched with aqueous 0.5 N HCl to pH ~2. Solvents were partially evaporated under reduced pressure, and the residue was extracted with EtOAc (2 × 100 mL). The combined organic portions were washed with saturated aqueous NaCl (100 mL), dried (Na₂SO₄), filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography using 40–70% EtOAc/hexanes as the eluent to afford the title compound **18d** (0.28 g, 60%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.28 (s, 1 H), 7.83 (d, $J = 9.2$ Hz, 1 H), 7.49 (dd, $J = 8.8, 2.8$ Hz, 1 H), 7.42 (d, $J = 2.8$ Hz, 1 H), 6.87 (s, 1 H), 5.92 (br s, 1 H), 5.70 (q, $J = 8.8$ Hz, 1 H), 5.13 (d, $J = 7.6$ Hz, 1 H), 4.97 (t, $J = 8.4$ Hz, 1 H), 4.62–4.56 (m, 2 H), 4.23–4.17 (m, 1 H), 4.01 (dd, $J = 11.6, 3.2$ Hz, 1 H), 3.94 (s, 3 H), 2.93–2.87 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, $J = 8.8$ Hz, 1 H), 1.95–1.54 (m, 2 H), 1.53–1.02 (m, 21 H), 0.96–0.88 (m, 1 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 176.99, 173.31, 167.91, 159.45, 154.93, 151.76, 138.27, 136.99, 136.32, 134.56 (q, $J = 36.2$ Hz), 127.99, 125.57, 124.53, 120.8 (q, $J = 274.0$ Hz), 107.40, 79.76, 75.54, 59.44, 55.89, 52.72, 51.86, 44.65, 34.61, 32.82, 31.02, 29.61, 28.02, 27.04, 25.99, 22.21, 20.93, 6.67, 6.12 ppm; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{36}H_{46}F_3N_6O_9S$, 795.2994; found 795.2974. Anal. HPLC: t_R 14.59 min, purity 100%.

***tert*-Butyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl)carbamate (19d)**—The same procedure was used as described above for compound **18d**. Acid **27d** (0.43 g, 0.62 mmol) was treated with CDI

(0.141 g, 0.87 mmol), 1-methylcyclopropanesulfonamide **29** (0.118 g, 0.87 mmol) and DBU (0.13 mL, 0.87 mmol) to afford the title compound **19d** (0.34 g, 68%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.15 (s, 1 H), 7.83 (d, *J* = 9.2 Hz, 1 H), 7.48 (dd, *J* = 9.2, 2.8 Hz, 1 H), 7.42 (d, *J* = 2.8 Hz, 1 H), 6.90 (s, 1 H), 5.91 (s, 1 H), 5.70 (q, *J* = 9.2 Hz, 1 H), 5.14 (d, *J* = 7.6 Hz, 1 H), 5.00 (t, *J* = 9.2 Hz, 1 H), 4.62–4.55 (m, 2 H), 4.24–4.18 (m, 1 H), 4.02 (dd, *J* = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.71–2.51 (m, 3 H), 2.33 (q, *J* = 8.4 Hz, 1 H), 1.93–1.75 (m, 4 H), 1.56–1.18 (m, 21 H), 0.85–0.78 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.30, 173.46, 167.15, 159.68, 155.16, 152.01, 138.50, 137.23, 136.50, 134.60 (q, *J* = 36.0 Hz), 128.23, 125.79, 125.19, 120.83 (d, *J* = 274.0 Hz), 107.65, 80.01, 75.79, 59.70, 56.12, 52.97, 52.08, 45.03, 36.65, 34.86, 33.06, 29.81, 28.26, 27.31, 27.24, 26.32, 22.47, 21.21, 18.42, 14.73, 12.77 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₄₈F₃N₆O₉S, 809.3150; found 809.3129. Anal. HPLC: *t*_R 15.23 min, purity 99%.

Cyclopentyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-14a-((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*]

[1,4]diazacyclopentadecin-6-yl)carbamate (22d)—Compound **18d** (0.40 g, 0.52 mmol) was treated with a solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, and the residue was dried under high vacuum. The pale yellow solid was triturated with diethyl ether (3 × 10 mL) and dried under high vacuum to yield the amine salt **20d** (0.37 g, 100%) as a white powder.

A solution of the above amine salt **20d** (0.37 g, 0.52 mmol) in anhydrous CH₃CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and *N*-(cyclopentylloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction mixture was stirred at room temperature for 24 h, then concentrated under reduced pressure and dried under high vacuum. The residue was purified by flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the target compound **22d** (0.30 g, 74%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.27 (s, 1 H), 7.82 (d, *J* = 9.2 Hz, 1 H), 7.48 (dd, *J* = 9.2, 2.8 Hz, 1 H), 7.42 (d, *J* = 2.8 Hz, 1 H), 6.78 (s, 1 H), 5.95 (s, 1 H), 5.70 (q, *J* = 9.6 Hz, 1 H), 5.23 (d, *J* = 8.0 Hz, 1 H), 4.98 (t, *J* = 8.8 Hz, 1 H), 4.74–4.69 (m, 1 H), 4.60 (t, *J* = 7.6, 1 H), 4.54 (d, *J* = 11.6, 1 H), 4.25–4.19 (m, 1 H), 3.99 (dd, *J* = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.88 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, *J* = 8.8 Hz, 1 H), 1.94–1.24 (m, 21 H), 1.20–1.07 (m, 2 H), 0.96–0.89 (m, 1 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.33, 173.29, 168.27, 159.68, 155.87, 152.08, 138.56, 137.24, 136.47, 134.74 (q, *J* = 36.0 Hz), 128.24, 125.75, 124.79, 120.87 (d, *J* = 273.2 Hz), 107.62, 78.02, 75.70, 59.68, 56.11, 52.90, 52.35, 44.83, 34.71, 32.92, 32.81, 32.64, 31.26, 29.87, 27.27, 26.24, 23.81, 23.75, 22.49, 21.11, 6.89, 6.34 ppm; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₇H₄₆F₃N₆O₉S, 807.2994; found 807.2976. Anal. HPLC: *t*_R 14.98 min, purity 99%.

Cyclopentyl ((2*R*,6*S*,13*aS*,14*aR*,16*aS*,*Z*)-2-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,

14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a]

[1,4]diazacyclopentadecin-6-yl)carbamate (23d)—The same procedure was used as described above for compound **22d**. Compound **19d** (0.40 g, 0.52 mmol) was treated with 4 N HCl in 1,4-dioxane (10 mL) to yield the amine salt **21d**, which was treated with DIEA (0.35 mL, 2.1 mmol) and *N*-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide the target compound **23d** (0.30 g, 74%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.18 (s, 1 H), 7.83 (d, *J* = 9.6 Hz, 1 H), 7.48 (dd, *J* = 8.8, 2.8 Hz, 1 H), 7.41 (d, *J* = 2.8 Hz, 1 H), 6.94 (s, 1 H), 5.94 (s, 1 H), 5.70 (q, *J* = 8.8 Hz, 1 H), 5.28 (d, *J* = 7.6 Hz, 1 H), 5.00 (t, *J* = 8.8 Hz, 1 H), 4.74–4.69 (m, 1 H), 4.60 (t, *J* = 7.6, 1 H), 4.54 (d, *J* = 12.0, 1 H), 4.25–4.19 (m, 1 H), 4.00 (dd, *J* = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.68–2.50 (m, 3 H), 2.31 (q, *J* = 8.4 Hz, 1 H), 1.92–1.20 (m, 24 H), 0.85–0.78 (m, 2 H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 177.33, 173.25, 167.13, 159.68, 155.84, 152.08, 138.56, 137.24, 136.44, 134.75 (q, *J* = 35.2 Hz), 128.25, 125.74, 125.21, 120.86 (d, *J* = 274.0 Hz), 107.62, 78.02, 75.71, 59.73, 56.12, 52.89, 52.34, 45.03, 36.65, 34.73, 32.93, 32.82, 32.64, 29.83, 27.26, 27.21, 26.29, 23.81, 23.75, 22.52, 21.23, 18.42, 14.73, 12.76 ppm. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₈H₄₈F₃N₆O₉S, 821.3150; found 821.3133. Anal. HPLC: *t*_R 15.65 min, purity 97%.

Enzyme Inhibition Assays

For each assay, 2 nM of NS3/4A protease (GT1a, D168A and GT3a) was pre-incubated at room temperature for 1 h with increasing concentration of inhibitors in assay buffer [50 mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% dimethyl sulfoxide]. Inhibition assays were performed in nonbinding surface 96-well black half-area plates (Corning) in a reaction volume of 60 μL. The proteolytic reaction was initiated by the injection of 5 μL of HCV NS3/4A protease substrate (AnaSpec), to a final concentration of 200 nM and kinetically monitored using a Perkin Elmer EnVision plate reader (excitation at 485 nm, emission at 530 nm). Three independent data sets were collected for each inhibitor with each protease construct. Each inhibitor titration included at least 12 inhibitor concentration points, which were globally fit to the Morrison equation to obtain the *K*_i value.

Cell-Based Drug Susceptibility Assays

Mutations (R155K, A516T, D168A and D168V) were constructed by site-directed mutagenesis using a Con1 (genotype 1b) luciferase reporter replicon containing the H77 (genotype 1a) NS3 sequence.⁵⁰ Replicon RNA of each protease variant was introduced into Huh7 cells by electroporation. Replication was then assessed in the presence of increasing concentrations of protease inhibitors by measuring luciferase activity (relative light units) 96 h after electroporation. The drug concentrations required to inhibit replicon replication by 50% (EC₅₀) were calculated directly from the drug inhibition curves.

Crystallization and structure determination

Protein expression and purification were carried out as previously described (see Supporting Information for details).³² The Ni-NTA purified WT1a protein was thawed, concentrated to 3 mg/mL, and loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, pH 6.5). The protease

fractions were pooled and concentrated to 25 mg/mL with an Amicon Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were incubated for 1 h with 3:1 molar excess of inhibitor. Diffraction-quality crystals were obtained overnight by mixing equal volumes of concentrated protein solution with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 4% ammonium sulfate, pH 6.5) at RT or 15 °C in 24-well VDX hanging drop trays. Crystals were harvested and data was collected at 100 K. Cryogenic conditions contained the precipitant solution supplemented with 15% glycerol or ethylene glycol.

Diffraction data were collected using an in-house Rigaku X-ray system with a Saturn 944 detector. All datasets were processed using HKL-3000.⁵¹ Structures were solved by molecular replacement using PHASER.⁵² The WT-2 complex structure (PDB code: 5EPN)³⁸ was used as the starting structure for all structure solutions. Model building and refinement were performed using Coot⁵³ and PHENIX,⁵⁴ respectively. The final structures were evaluated with MolProbity⁵⁵ prior to deposition in the PDB. To limit the possibility of model bias throughout the refinement process, 5% of the data were reserved for the free R-value calculation.⁵⁶ Structure analysis, superposition and figure generation were done using PyMOL.⁵⁷ X-ray data collection and crystallographic refinement statistics are presented in the Supporting Information (Table S3).

Molecular Modeling

Molecular modeling was carried out using MacroModel (Schrödinger, LLC, New York, NY).⁵⁸ Briefly, inhibitors were modeled into the active site of WT1a and A156T proteases using the WT-2 and A156T-2 co-complex structures (PDB code: 5EPN and 5EPY).³⁸ Structures were prepared using the Protein Preparation tool in Maestro 11. 2D chemical structures were modified with the appropriate changes using the Build tool in Maestro. Once modeled, molecular energy minimizations were performed for each inhibitor–protease complex using the PRCG method with 2500 maximum iterations and 0.05 gradient convergence threshold. PDB files of modeled complexes were generated in Maestro for structural analysis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by a grant from the National Institute of Allergy and Infectious Diseases of the NIH (R01 AI085051). ANM was also supported by the National Institute of General Medical Sciences of the NIH (F31 GM119345). MJ was supported by a Postdoctoral Fellowship from the Higher Education Commission of Pakistan (HEC). We thank Dr. Kiran K. Reddy and members of the Schiffer and Miller laboratories for helpful discussions.

ABBREVIATIONS

CDI	1,1'-carbonyldiimidazole
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
1,2-DCE	1,2-dichloroethane

DIEA	<i>N,N</i> -diisopropylethylamine
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethyl sulfoxide
EtOAc	ethyl acetate
GT	genotype
HATU	1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]-pyridinium 3-oxid hexafluorophosphate
NMP	<i>N</i> -methylpyrrolidinone
PI	protease inhibitor
RT	room temperature
SAR	structure– activity relationship
THF	tetrahydrofuran
WT	wild-type

References

1. World Health Organization (WHO). [Accessed February 6: 2016] Hepatitis C, Fact Sheet. (Updated July 2016): <http://www.who.int/mediacentre/factsheets/fs164/en/>
2. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nat Rev Gastroenterol Hepatol*. 2013; 10:553–562. [PubMed: 23817321]
3. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hezode C, Lazaro P, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandao Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergor G, Esmat G, Falconer K, Felix J, Ferraz ML, Ferreira PR, Frankova S, Garcia-Samaniego J, Gerstoft J, Gira JA, Goncalves FL Jr, Gower E, Gschwandler M, Guimaraes Pessoa M, Hindman SJ, Hofer H, Huse P, Kaberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Ormeci N, Ovrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Starkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Mullhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat*. 2014; 21(Suppl 1):34–59. [PubMed: 24713005]
4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*. 2014; 61:S45–S57. [PubMed: 25086286]
5. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015; 61:77–87. [PubMed: 25069599]
6. [Accessed February 6: 2017] Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Apr. 2016 Updated version <http://www.who.int/hepatitis/publications/hepatitis-cguidelines-2016/en/>

7. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. *Liver Int.* 2016; 36:47–57. [PubMed: 26725897]
8. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med.* 2014; 370:1889–1898. [PubMed: 24725239]
9. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med.* 2014; 370:1983–1992. [PubMed: 24795200]
10. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet.* 2014; 385:1075–1086. [PubMed: 25467591]
11. Everson GT, Townner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir with velpatasvir in treatment-naïve noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. *Ann Intern Med.* 2015; 163:818–826. [PubMed: 26551051]
12. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. *Gastroenterology.* 2016; 151:70–86. [PubMed: 27080301]
13. Meanwell NA. 2015 Philip S. Portuguese Medicinal Chemistry Lectureship. Curing hepatitis C virus infection with direct-acting antiviral agents: the arc of a medicinal chemistry triumph. *J Med Chem.* 2016; 59:7311–7351. [PubMed: 27501244]
14. McCauley JA, Rudd MT. Hepatitis C virus NS3/4a protease inhibitors. *Curr Opin Pharmacol.* 2016; 30:84–92. [PubMed: 27544488]
15. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. *Nat Biotech.* 2011; 29:993–1003.
16. Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V, Njoroge FG. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. *J Med Chem.* 2006; 49:6074–6086. [PubMed: 17004721]
17. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med.* 2011; 364:2417–2428. [PubMed: 21696308]
18. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011; 364:1195–1206. [PubMed: 21449783]

19. Rosenquist Å, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-Mauviel M. Discovery and development of simeprevir (TMC435) a HCV NS3/4A protease inhibitor. *J Med Chem*. 2014; 57:1673–1693. [PubMed: 24446688]
20. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. *Antimicrob Agents Chemother*. 2015; 59:988–997. [PubMed: 25451053]
21. Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, Koch U, Petrocchi A, Holloway MK, Butcher JW, Romano JJ, Bush KJ, Gilbert KF, McIntyre CJ, Nguyen KT, Nizi E, Carroll SS, Ludmerer SW, Burlein C, DiMuzio JM, Graham DJ, McHale CM, Stahlhut MW, Olsen DB, Monteagudo E, Cianetti S, Giuliano C, Pucci V, Trainor N, Fandozzi CM, Rowley M, Coleman PJ, Vacca JP, Summa V, Liverton NJ. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. *ACS Med Chem Lett*. 2012; 3:332–336. [PubMed: 24900473]
22. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonna RJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. *J Med Chem*. 2014; 57:1730–1752. [PubMed: 24564672]
23. McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. *J Med Chem*. 2010; 53:2443–2463. [PubMed: 20163176]
24. Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. *Antimicrob Agents Chemother*. 2015; 60:1546–1555. [PubMed: 26711747]
25. Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study. *J Viral Hepat*. 2016; 23:614–622. [PubMed: 26957110]
26. Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukulj G, LaPlante SR, Llinas-Brunet M, Nar H, Lamarre D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. *Angew Chem Int Ed Engl*. 2003; 42:1356–1360. [PubMed: 12671967]
27. LaPlante SR, Nar H, Lemke CT, Jakalian A, Aubry N, Kawai SH. Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease. *J Med Chem*. 2013; 57:1777–1789. [PubMed: 24144444]
28. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. *Hepatology*. 2015; 62:1623–1632. [PubMed: 26095927]
29. Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. *Curr Opin Virol*. 2014; 8:16–21. [PubMed: 24852142]
30. Chan, K., Yu, M., Peng, B., Corsa, A., Worth, A., Gong, R., Xu, S., Chen, X., Appleby, TC., Taylor, J., Delaney, WE., Cheng, G. In vitro efficacy and resistance profiling of protease inhibitors against a novel HCV genotype 3a replicon. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; Toronto, ON, Canada. 2013.
31. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. *Proc Natl Acad Sci U S A*. 2010; 107:20986–20991. [PubMed: 21084633]

32. Romano KP, Ali A, Aydin C, Soumana D, Özen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. *PLoS Pathog.* 2012; 8:e1002832. [PubMed: 22910833]
33. Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. *ACS Chem Biol.* 2014; 9:2485–2490. [PubMed: 25243902]
34. Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. *J Am Chem Soc.* 2016; 138:11850–11859. [PubMed: 27512818]
35. O'Meara JA, Lemke CT, Godbout C, Kukolj G, Lagacé L, Moreau B, Thibeault D, White PW, Llinàs-Brunet M. Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance. *J Biol Chem.* 2013; 288:5673–5681. [PubMed: 23271737]
36. Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Özen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. *ACS Chem Biol.* 2013; 8:1469–1478. [PubMed: 23594083]
37. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, DiMuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, McHale C, Montegudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. *Antimicrob Agents Chemother.* 2012; 56:4161–4167. [PubMed: 22615282]
38. Soumana DI, Kurt Yilmaz N, Prachanronarong KL, Aydin C, Ali A, Schiffer CA. Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172. *ACS Chem Biol.* 2016; 11:900–909. [PubMed: 26682473]
39. King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Combating susceptibility to drug resistance: lessons from HIV-1 protease. *Chem Biol.* 2004; 11:1333–1338. [PubMed: 15489160]
40. Özen A, Sherman W, Schiffer CA. Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design. *J Chem Theory Comput.* 2013; 9:5693–5705. [PubMed: 24587770]
41. Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving viral protease inhibitors to counter drug resistance. *Trends Microbiol.* 2016; 24:547–557. [PubMed: 27090931]
42. Wang, XA., Sun, L-Q., Sit, S-Y., Sin, N., Scola, PM., Hewawasam, P., Good, AC., Chen, Y., Campbell, A. Hepatitis C Virus Inhibitors. US Patent. 6995174. 2006.
43. Rudd MT, Butcher JW, Nguyen KT, McIntyre CJ, Romano JJ, Gilbert KF, Bush KJ, Liverton NJ, Holloway MK, Harper S, Ferrara M, DiFilippo M, Summa V, Swestock J, Fritzen J, Carroll SS, Burlein C, DiMuzio JM, Gates A, Graham DJ, Huang Q, McClain S, McHale C, Stahlhut MW, Black S, Chase R, Soriano A, Fandozzi CM, Taylor A, Trainor N, Olsen DB, Coleman PJ, Ludmerer SW, McCauley JA. P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325. *ChemMedChem.* 2015; 10:727–735. [PubMed: 25759009]
44. Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, Lindstrom S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. *Bioorg Med Chem Lett.* 2008; 18:6189–6193. [PubMed: 18954982]
45. Moreau B, O'Meara JA, Bordeleau J, Garneau M, Godbout C, Gorys V, Leblanc M, Villemure E, White PW, Llinàs-Brunet M. Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution. *J Med Chem.* 2014; 57:1770–1776. [PubMed: 23506530]
46. Gillis, EP., Bowsher, MS., McPhee, F., Jenkins, S., Wang, Y-K., Scola, PM., Meanwell, NA. In Abstract of Papers, 2nd Generation HCV protease inhibitors: Part 2, optimization of P2*; 250th ACS National Meeting & Exposition; Boston, MA, United States. August 16–20: 2015; p. MEDI-240

47. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. *J Med Chem.* 2011; 54:2529–2591. [PubMed: 21413808]
48. Or, YS., Moore, JD., Liu, D., Sun, Y., Gai, Y., Tang, D., Niu, D., Xu, G., Wang, Z. Quinoxalinyll Macrocyclic Hepatitis C Virus Serine Protease Inhibitors. *PCT Int Appl. WO 2008/002924.* Jan 03. 2008
49. Sun, L-Q., Mull, E., Gillis, EP., Bowsher, MS., Zhao, Q., Renduchintala, VK., Sarkunam, K., Nagalakshmi, P., Babu, PVKS., Scola, PM. Hepatitis C Virus Inhibitors. *PCT Int Appl. WO 2014/062196.* Apr 24. 2014
50. Sarkar G, Sommer SS. The “megaprimer” method of site-directed mutagenesis. *Biotechniques.* 1990; 8:404–407. [PubMed: 2340178]
51. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 1997; 276:307–326.
52. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J Appl Crystallogr.* 2007; 40:658–674. [PubMed: 19461840]
53. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr.* 2004; 60:2126–2132. [PubMed: 15572765]
54. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:213–221. [PubMed: 20124702]
55. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, Snoeyink J, Richardson JS, Richardson DC. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucl Acids Res.* 2007; 35:W375–W383. [PubMed: 17452350]
56. Brunger AT. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. *Nature.* 1992; 355:472–475. [PubMed: 18481394]
57. PyMOL. The PyMOL Molecular Graphics System, Version 1.8. Schrödinger, LLC;
58. Schrödinger Release 2017-1. Schrödinger, LLC; New York, NY, United States: 2017.

Figure 1.
Chemical structures of HCV NS3/4A protease inhibitors. Simeprevir, paritaprevir and grazoprevir are approved by the FDA; voxilaprevir and glecaprevir are in clinical development.

Figure 2.

Chemical structures and binding modes of grazoprevir (**1**) and analogue **2**. (a) Compound **2** was designed by replacing the P2–P4 macrocycle in **1** with a P1–P3 macrocycle. (b) The binding conformation of **1** (PDB code: 3SUD) and **2** (PDB code: 5EPN) in the active site of wild-type NS3/4A protease. Compound **2** maintains the unique binding mode of **1** whereby the P2 quinoxaline makes strong interactions with the catalytic residues avoiding contacts with known drug resistance residues. The catalytic triad is highlighted in yellow and drug resistance residues Arg155, Ala156, and Asp168 are shown in blue, red and green, respectively. The canonical nomenclature for drug moiety positioning is indicated using grazoprevir.

Figure 3.

(a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor **19b** and (b) superposition of WT-2 and WT-**19a** complexes. The protease active site is shown as a surface with inhibitor **19b** shown in orange and **2** shown in blue. The catalytic triad is highlighted in yellow and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.

Figure 4. Comparison of lead compound **2** with analogues (a) **18d**, and (b) **18e**, modeled in the active site of WT HCV NS3/4A protease. Compound **2** is shown in salmon and modified inhibitors are in green. The catalytic triad is highlighted in yellow and drug resistance residues Arg155, Ala156, and Asp168 are in sticks.

Figure 5.

(a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with inhibitor **18f** and (b) superposition of WT-2 and WT-**18f** complexes. The protease active site is shown as a surface with inhibitor **18f** shown in orange and **2** shown in blue. The catalytic triad is highlighted in yellow and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks.

Figure 6.

Resistance profiles of protease inhibitors in enzyme inhibition and antiviral assays for PIs with (a) *tert*-butyl and (b) cyclopentyl P4 capping groups. Enzyme inhibitory (blue bars) and antiviral (orange bars) activities against the D168A variant were normalized with respect to the wild-type NS3/4A protease domain or wild-type HCV replicon. *Indicates value higher than 1000.

Scheme 1.

Synthesis of HCV NS3/4A protease inhibitors. Reagents and conditions: (a) Cs_2CO_3 , NMP, 55 °C, 6 h; (b) 4 N HCl in dioxane, CH_2Cl_2 , RT, 3 h; (c) HATU, DIEA, DMF, RT, 4 h; (d) $\text{LiOH} \cdot \text{H}_2\text{O}$, THF, H_2O , RT, 24 h; (e) HATU, DIEA, DMF, RT, 2 h; (f) Zhan 1B catalyst, 1,2-DCE, 70 °C, 6 h; (g) 4 N HCl, dioxane, RT, 3 h; (h) *N*-(cyclopentyloxycarbonyloxy)-succinimide, DIEA, CH_3CN , RT, 36 h.

Scheme 2.

Alternate synthesis of HCV NS3/4A protease inhibitors. Reagents and conditions: (a) HATU, DIEA, DMF, RT, 2 h; (b) Zhan 1B catalyst, 1,2-DCE, 70 °C, 5 h; (c) LiOH.H₂O, THF, MeOH, H₂O, RT, 24 h; (d) CDI, THF, DBU, reflux, 1.5 h, RT, 36 h.

Table 1

Inhibitory activity against wild-type NS3/4A protease and drug resistant variants

Inhibitor	R ¹	R ²	R ³	K _i (nM)		
				GT1a WT NS3/4A Protease	GT1a D168A NS3/4A Protease	GT3a NS3/4A Protease
2	OMe	Et	H	3.29 ± 0.52	82.4 ± 4.4	204 ± 19
19a	OMe	Et	Me	1.82 ± 0.38	55.2 ± 5.3	171 ± 23
22a	OMe	Et	H	1.24 ± 0.14	52.3 ± 3.2	211 ± 18
23a	OMe	Et	Me	1.37 ± 0.34	55.2 ± 5.3	186 ± 30
18b	OMe	Me	H	3.40 ± 0.47	50.9 ± 3.7	152 ± 18
19b	OMe	Me	Me	3.60 ± 0.44	52.0 ± 2.4	119 ± 18
22b	OMe	Me	H	0.93 ± 0.15	31.9 ± 2.5	147 ± 20
23b	OMe	Me	Me	1.13 ± 0.22	36.3 ± 1.8	121 ± 16
18c	OMe	Cl	H	1.07 ± 0.17	39.8 ± 3.4	67.5 ± 8.0
19c	OMe	Cl	Me	1.11 ± 0.38	77.7 ± 6.1	53.6 ± 5.9
22c	OMe	Cl	H	0.49 ± 0.15	30.6 ± 2.6	85.6 ± 11
23c	OMe	Cl	Me	0.44 ± 0.15	25.7 ± 1.8	61.0 ± 12
18d	OMe	CF ₃	H	13.3 ± 3.9	157 ± 12	344 ± 141
19d	OMe	CF ₃	Me	5.77 ± 1.78	118 ± 13	231 ± 74
22d	OMe	CF ₃	H	7.55 ± 2.39	115 ± 12	757 ± 334
23d	OMe	CF ₃	Me	8.14 ± 2.37	110 ± 14	433 ± 206

Inhibitor	R ¹	R ²	R ³	K _i (nM)		
				GT1a WT NS3/4A Protease	GT1a D168A NS3/4A Protease	GT3a NS3/4A Protease
18e	OMe	<i>i</i> -Pr	H	4.27 ± 1.34	239 ± 20	NT
19e	OMe	<i>i</i> -Pr	Me	0.58 ± 0.08	211 ± 19	NT
22e	OMe	<i>i</i> -Pr	H	1.44 ± 0.46	161 ± 11	NT
23e	OMe	<i>i</i> -Pr	Me	1.34 ± 0.48	156 ± 17	NT
18f	H	2-thiophene	H	1.03 ± 0.13	1823 ± 347	NT
22f	H	2-thiophene	H	1.59 ± 0.56	900 ± 81	NT
18g	H	Et	H	7.18 ± 1.02	190 ± 13	NT
22g	H	Et	H	1.99 ± 0.48	107 ± 7.0	NT
GZR (1)				0.21 ± 0.03	49.1 ± 1.6	30.3 ± 1.9

NT: not tested

Table 2

Antiviral activity against wild-type HCV and drug resistant variants.

Inhibitor	R ¹	R ²	R ³	Replicon EC ₅₀ (nM)			
				WT	R155K	A156T	D168A D168V
2	OMe	Et	H	0.33	1.75	9.65	6.31 9.10
19a	OMe	Et	Me	0.43	1.80	4.52	4.97 6.42
22a	OMe	Et	H	0.14	2.08	11.8	3.60 11.9
23a	OMe	Et	Me	0.16	2.07	10.6	3.45 7.08
18b	OMe	Me	H	0.39	1.17	5.95	4.24 3.17
19b	OMe	Me	Me	0.30	0.80	1.57	2.37 1.60
22b	OMe	Me	H	0.11	0.89	2.88	2.63 4.32
23b	OMe	Me	Me	0.13	1.09	3.99	2.16 2.85
18c	OMe	Cl	H	0.16	0.44	16.2	1.42 0.73
19c	OMe	Cl	Me	0.18	0.40	8.86	1.07 0.49
22c	OMe	Cl	H	0.15	0.59	3.55	1.32 1.55
23c	OMe	Cl	Me	0.15	0.56	4.32	0.97 1.09
18d	OMe	CF ₃	H	1.98	3.45	36.2	16.8 17.1
19d	OMe	CF ₃	Me	1.52	2.30	20.5	8.64 8.31
22d	OMe	CF ₃	H	4.86	7.97	117	15.1 24.0
23d	OMe	CF ₃	Me	4.04	6.90	75.9	8.46 11.4

Inhibitor	R ¹	R ²	R ³	Replicon EC ₅₀ (nM)				
				WT	R155K	A156T	D168A	D168V
18e	OMe	i-Pr	H	1.43	5.02	25.7	15.3	23.7
19e	OMe	i-Pr	Me	1.86	4.14	21.2	11.9	18.1
22e	OMe	i-Pr	H	0.48	7.63	32.1	7.96	30.1
23e	OMe	i-Pr	Me	0.59	6.83	27.6	7.91	18.2
18f	H	2-thiophene	H	0.98	21.7	256	111	193
22f	H	2-thiophene	H	0.40	19.2	183	42.2	70.0
18g	H	Et	H	0.46	1.81	10.6	8.55	14.0
22g	H	Et	H	0.24	4.28	24.6	7.50	19.3
GZR (I)				0.14	1.89	238	9.69	5.41